Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by BudFox87on Sep 17, 2018 9:45am

71 Views

Post# 28631862

SPlit impact on warrants, TSX bulletin 2018-0397

This is the real info:

As a result of the stock consolidation, 9.5 Warrants will be exercisable into one post-consolidated Common Share on and after May 25, 2018, at an exercise price of $9.025 per Common Share at any time before 5:00 p.m. (Calgary time) on June 1, 2022.

Bullboard Posts

Gold vs. bitcoin, where should you invest?